A Systems Pharmacology Perspective on the Clinical Development of Fatty Acid Amide Hydrolase Inhibitors for Pain

The level of the endocannabinoid anandamide is controlled by fatty acid amide hydrolase (FAAH). In 2011, PF-04457845, an irreversible inhibitor of FAAH, was progressed to phase II clinical trials for osteoarthritic pain. This article discusses a prospective, integrated systems pharmacology model eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Benson, N, Metelkin, E, Demin, O, Li, G L, Nichols, D, van der Graaf, P H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910012/
https://www.ncbi.nlm.nih.gov/pubmed/24429592
http://dx.doi.org/10.1038/psp.2013.72

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910012/
https://www.ncbi.nlm.nih.gov/pubmed/24429592
http://dx.doi.org/10.1038/psp.2013.72

Ejemplares similares